Aptose Announces Updated Clinical Responses, Breadth of
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib...
United States American Society Of Hematology Company Provides Comprehensive Clinical Department Of Leukemia Hanmi Pharmaceutical Company Aptose Biosciences Inc
Source: globenewswire.com